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Abstract Reliable diagnoses of sepsis remain challenging 
in forensic pathology routine despite improved methods 
of sample collection and extensive biochemical and im-
munohistochemical investigations. Macroscopic findings 
may be elusive and have an infectious or non-infectious 
origin. Blood culture results can be difficult to interpret 
due to postmortem contamination or bacterial transloca-
tion. Lastly, peripheral and cardiac blood may be unavail-
able during autopsy. Procalcitonin, C-reactive protein, and 
interleukin-6 can be measured in biological fluids collect-
ed during autopsy and may be used as in clinical practice 
for diagnostic purposes. However, concentrations of these 
parameters may be increased due to etiologies other than 
bacterial infections, indicating that a combination of bi-
omarkers could more effectively discriminate non-infec-
tious from infectious inflammations. In this article, we pro-
pose a review of the literature pertaining to the diagnostic 
performance of classical and novel biomarkers of inflam-
mation and bacterial infection in the forensic setting.
Worldwide, sepsis and its sequels are still a common cause 
of acute illness and death in patients with community-ac-
quired and nosocomial infections (1). Multiple organ dys-
function syndrome (MODS) is common in critical cases of 
severe sepsis and a primary cause of death (2). The Ameri-
can College of Chest Physicians and the Society of Criti-
cal Care Medicine Consensus Conference (Northbrook, IL, 
USA; August 1991) defined sepsis as a systemic inflamma-
tion response caused by infection (1,3,4). However, in the 
early stages of the process, the source of infection may be 
unclear and the related systemic response indistinguish-
able from non-infectious disease. Consequently, diagnosis 
may be missed or delayed, posing a serious concern since 
strong evidence associates early treatment with greater 
clinical success (5,6). At present, there is no ideal, clinical 
gold standard for the diagnosis of sepsis, as microbiology 
is not sensitive enough and laboratory tests unspecific for 
use as a reference standard (1,2,5).
Bacteremia is identified in only a portion of patients with 
sepsis, also depending on previous antibiotic treatment. 
Culture-negative patients accounted for percentages rang-
ing from 25% to 48% of all septic cases in a series of clinical 
studies performed in North America, Europe, and Asia (1,7).
Early clinical signs, such as fever, tachycardia, and leukoci-
tosis, are usually unspecific and overlap with signs of sys-
temic inflammatory response syndrome (SIRS) of non-
infectious origin. More specific signs of sepsis, such as 
arterial hypotension, thrombocytopenia, and increased 
lactate concentration, often indicate progression to organ 
dysfunction (1,8).
Though C-reactive protein (CRP) and procalcitonin are cur-
rently used as clinical indicators of inflammation and infec-
tion, several other biochemical markers have been investi-
gated for their ability to detect sepsis in an early, reversible 
phase (1,3). Nonetheless, identification of an ideal bio-
marker (or panel of biomarkers) capable of making a clear 
distinction between sepsis and SIRS is imperative (2).
Reliable diagnoses of sepsis remain challenging in the fo-
rensic field, despite improved methods of collecting blood 
and tissue samples for postmortem bacteriology and ex-
tensive research in biochemical and immunohistochemical 
investigations. There are a myriad of reasons for this difficul-
ty in diagnosis, such as the fact that forensic pathologists 
rarely have full access to medical records before autopsy 
is performed. Furthermore, macroscopic findings (myo-
cardial ischemia, pulmonary edema, hypoxic liver dam-
age, mesenteric ischemia, gastrointestinal hemorrhages, 
spleen infarction, kidney ischemia, and brain edema) and 
histological observations may be elusive or non-specific 
and have an infectious or non-infectious origin. In addi-
tion, blood culture results can be difficult to interpret due 
to contamination during sampling procedures or bacte-
rial translocation. Postmortem samples might also prove 
insufficient, unavailable, or absent during autopsy, es-
pecially in infant autopsy. Procalcitonin, CRP, and in-
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terleukin-6 can be measured in biological fluids collected 
during autopsy and may be used as in clinical practice for 
diagnostic purposes. However, the concentrations of these 
parameters can be increased due to etiologies other than 
bacterial infections. Hence, as in the clinical field, in recent 
years other laboratory parameters have been investigated 
in order to define the most suitable biomarker (or combi-
nation of biomarkers) that might more effectively discrimi-
nate non-infectious from infectious inflammations (9-15).
The identification of reliable markers of sepsis in the foren-
sic setting is, however, more difficult than in the clinical field. 
Indeed, biochemical profiles after death may show consid-
erable variations consequent to various factors including 
survival time, molecule leakage from necrotic or damaged 
cells due to rapid cell membrane breakdown, molecule re-
distribution dependent on concentration gradients, and 
molecule denaturation. All these factors therefore limit the 
application of postmortem biochemistry to relatively stable 
markers and only some, specific biological fluids (16-18). 
The aim of this article is to propose a review of the literature 
pertaining to the diagnostic performance of classical and 
novel biomarkers of sepsis in forensic pathology routine.
ProCAlCitonin
High serum procalcitonin concentrations were first de-
scribed in children with severe bacterial infections by As-
sicot et al (19), and were suggested as a specific marker for 
bacterial infection. Procalcitonin, the precursor of the hor-
mone calcitonin, is a glycoprotein consisting of 116 amino 
acids with a molecular weight of 13 kDa. Gene products 
transcribed from the CALC-I gene (located on the short 
arm of the human chromosome 11) represent a large array 
of related proteins including calcitonin gene-related pep-
tide, amyllin, adrenomedullin, and calcitonin (calcitonin 
family) that are restricted to neuroendocrine cells of the 
thyroid under normal metabolic conditions. Only one of 
these peptides, procalcitonin, seems to play a pivotal role 
in the host response to microbial infections. Procalcitonin is 
produced from the common precursor, pre-procalcitonin, 
which consists of 141 amino acid residues by removal of 
25 amino acids from the N-terminus. Procalcitonin is made 
up of a centrally placed calcitonin (a 32-amino acid pep-
tide) and two flanking peptides, N-terminal region (a 57-
amino acid peptide), and katalcin (a 21-amino acid pep-
tide). Regular enzymatic processing and further cleavage 
in the C-cells of the thyroid gland result in the production 
of mature procalcitonin. In the absence of infection, the 
extra-thyroid transcription of the CALC-I gene is sup-
pressed. However, during bacterial infections, pre-procal-
citonin mRNA is ubiquitously expressed in various extra-
thyroid neuroendocrine tissues and non-neuroendocrine 
parenchymal cells throughout the body. Consequently, 
under septic circumstances, procalcitonin is released into 
the bloodstream by a continuous constitutive pathway. 
Elevated concentrations of procalcitonin during severe 
bacterial infections are commonly observed in patients 
who had already undergone total thyroidectomy. In pa-
tients with sepsis, non-neuroendocrine parenchymal cells 
are stimulated to produce and secrete large amounts of 
procalcitonin. However, these lack the post-translational 
capacity of neuroendocrine cells to biosynthesize mature 
calcitonin hormone from procalcitonin. A significant in-
crease in calcitonin during sepsis therefore rarely occurs. 
Though hepatocytes may produce procalcitonin, it is still 
debated whether the liver and splancnic area produce pro-
calcitonin during infections (3,8,20-25).
Systemic activation of immunocompetent cells in response 
to microorganisms or microbial endotoxin induces inflam-
matory cytokine release at the infection site. This is the piv-
otal mechanism in the pathogenesis of the sepsis cascade. 
Even though procalcitonin is not produced by circulating 
blood cells, its synthesis seems to be closely dependent on 
the cytokines involved in initiating the inflammatory cas-
cade. Procalcitonin can be detected after 3-4 hours in re-
sponse to bacterial endotoxins and peaks at 6-8 hours with 
a half-life of approximately 24-30 hours (8,20-22).
In healthy individuals, all the procalcitonin produced in C-
cells is converted to calcitonin, so that circulating procal-
citonin concentrations are below detection levels of 0.1 
ng/mL (0.1 μg/L). In patients with sepsis, procalcitonin 
concentration may increase up to 5000 to 10 000 times 
with calcitonin still in the reference range. No enzymes in 
blood can break down the procalcitonin circulating mol-
ecule (8,20,22).
The physiologic role of procalcitonin is not yet complete-
ly understood. Bacterial endotoxins are the most potent 
stimulators of procalcitonin release, though gram-positive 
infections may also induce its production. Apart from bac-
terial infections, various situations of tissue damage in non-
infected patients such as prolonged cardiogenic shock, ma-
jor surgery, severe trauma, or burns, may induce increases in 
blood procalcitonin concentrations. However, blood levels 
observed under these conditions are usually not as high as 
those in patients with severe sepsis or septic shock. Hence, 
in cases of trauma or extensive surgery, increased level per-
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sistence as well as secondary procalcitonin increases at a 
later time may herald the onset of infectious complications. 
Local viral infections do not induce increased procalcitonin 
levels, whereas systemic viral infections may determine lev-
els as high as those noted in bacterial infections. Systemic 
fungal infections may be characterized by increased procal-
citonin levels, though concentrations tend to be lower than 
those in patients with bacterial infections. Conversely, infec-
tions by the malaria parasite often lead to very high serum 
procalcitonin levels (8,20,23).
Procalcitonin determination for the postmortem diagnosis 
of sepsis in the realm of forensic pathology was originally 
proposed by Tsokos et al (26). These authors measured pro-
calcitonin concentrations in postmortem serum obtained 
from septic and control cases and compared antemortem 
and postmortem procalcitonin values in septic cases. They 
observed increased procalcitonin levels in all septic cases 
and normal concentrations in most control cases. They 
also observed a postmortem decrease in procalcitonin 
values compared to antemortem levels, suggesting that 
the postmortem measurement of this marker seems rea-
sonable until at least 140 hours after death. These authors 
concluded that increased procalcitonin levels could be 
considered a reliable diagnostic tool for the postmortem 
diagnosis of sepsis. Furthermore, they proposed at least 
two positive postmortem procalcitonin values at different 
postmortem intervals in order to better estimate the most 
probable procalcitonin level at the time of death by using 
linear regression analysis.
Vitreous, pericardial, and cerebrospinal fluid procalcitonin 
levels in septic and control cases were investigated by 
Schrag et al (10,27), who reported promising results with 
vitreous and pericardial fluid procalcitonin concentrations 
in septic cases. Bode-Jänisch et al (28) measured procalci-
tonin concentrations in postmortem serum obtained from 
septic and control cases and compared postmortem levels 
to antemortem procalcitonin concentrations when avail-
able. The results confirmed the stability of procalcitonin in 
postmortem samples and the reliability of this biomarker 
in the postmortem diagnosis of bacterial sepsis.
C-reACtive Protein
CRP, named for its capacity to precipitate the somatic C-
polysaccharide of Streptococcus pneumoniae, was the 
first, acute-phase protein to be described. It is a systemic 
marker of inflammation and tissue damage, widely used in 
the diagnosis and management of various clinical condi-
tions. The acute-phase response comprises the nonspecific 
physiological and biochemical responses of endothermic 
animals to most forms of tissue damage, infection, inflam-
mation, and malignant neoplasia. In particular, the synthe-
sis of numerous proteins is rapidly up-regulated, mainly in 
hepatocytes, under the control of cytokines originating at 
the site of tissue damage. The human CRP molecule is com-
posed of five identical non-glycosylated polypeptide sub-
units, each containing 206 amino acid residues. In healthy 
young adults, the median concentration of CRP is 0.8 mg/L, 
the 90th percentile is 3.0 mg/L, and the 99th percentile is 10 
mg/L, but, following an acute-phase stimulus, values may 
increase to more than 500 mg/L, hence 10 000 times. Plas-
ma CRP is produced only by hepatocytes, predominantly 
under transcriptional control of IL-6, although other sites of 
local CRP synthesis and possibly secretion have been sug-
gested. De novo hepatic synthesis starts very rapidly after 
a single stimulus, concentrations rising above 5 mg/L by 
about 4 to 6 hours and peaking around 24 to 48 hours. CRP 
plasma half-life is about 19 hours and is constant under all 
conditions of health and disease, so that the sole determi-
nant of circulating CRP concentration is the synthesis rate, 
which thus directly reflects the intensity of the pathological 
process(es) stimulating its production (3,29-31).
CRP levels remain elevated during the acute response 
phase. When the stimulus for increased production com-
pletely ceases, the circulating CRP concentration falls rap-
idly and returns to within reference values when tissue 
damage is resolved. Due to its rapid response, short half-
life, and high magnitude of increase, CRP is a useful indica-
tor of the acute phase response in several situations. These 
may include infections (bacterial, viral, fungal, and myco-
bacterial), inflammatory diseases, necrosis (myocardial in-
farction, pancreatitis), trauma, and malignancy. In most, 
though not all, diseases, the circulating value of CRP re-
flects ongoing inflammation and/or tissue damage much 
more accurately than do other laboratory parameters of 
the acute-phase response. Acute-phase CRP values show 
no diurnal variation and are unaffected by eating. Liver 
failure impairs CRP production, but no other intercurrent 
pathologies and very few drugs reduce CRP values un-
less they also affect the underlying pathology providing 
the acute-phase stimulus. CRP concentration is thus a very 
useful, nonspecific biochemical marker of inflammation as 
well as an important measurement that may contribute to 
determining disease severity and progression (30,31).
In the forensic field, the diagnostic application of CRP 
determination was originally proposed by Laurier et 
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al (32). These authors measured CRP values in postmortem 
serum and pericardial fluid in a series of 26 forensic autop-
sies that were selected based on agony duration (long and 
short agonies). The results of this study showed statistically 
significant increases in CRP levels in both postmortem se-
rum and pericardial fluid in long agonies. The authors at-
tributed this result to agonal pericarditis possibly resulting 
from agonal myocardial necrosis.
Further studies focusing on CRP levels in postmortem 
samples have been performed by several other research 
teams (10,27,29,33-38). Uhlin-Hansen (33), Astrup and 
Thomsen (37), and Tsokos et al (34) compared antemor-
tem and postmortem CRP levels and observed increased 
concentrations of this marker in septic cases, reflecting the 
existence of ongoing inflammatory processes at the time 
of death. These authors also found that antemortem CRP 
levels were higher than postmortem concentrations, likely 
suggesting molecule proteolysis due to decompositional 
changes along with irrelevant postmortem molecule re-
lease from hepatocytes in the early postmortem period. 
Maeda et al (35) found low CRP levels in some infantile 
and elderly cases of pneumonia that were postulated as 
age-dependent, low inflammatory responses. Astrup and 
Thomsen (37) observed that CRP levels in postmortem se-
rum stored at 5°C were stable for several weeks. CRP levels 
measured in liver samples (collected from the central part 
of the right lobe), though less stable, correlated well with 
postmortem serum samples.
interelukin-6
Interleukin-6 (IL-6) is a multifunctional, proinflammatory cy-
tokine with pleiotropic expressions produced by a wide va-
riety of cell types (leukocytes, fibroblasts, and endothelial 
cells) in the early phase of inflammation. It is a 26 kDa pro-
tein that modulates a variety of functions and has a key role 
in the acute-phase inflammatory response, being the pri-
mary determinant of hepatic CRP production. In addition to 
this role, IL-6 is important in specific immunologic response 
development, including activated B cell differentiation, cul-
minating in the production of immunoglobulin (34,39-44).
IL-6 is normally not detected in the serum of healthy young 
individuals unless there is trauma, infection, or some other 
stress. Under these circumstances, IL-6 is rapidly expressed 
and contributes to a cascade of events typical of inflam-
mation. These include leukocytosis, lymphocyte acti-
vation, and acute-phase protein synthesis as well as a 
general catabolic shift in metabolic pathways (39).
IL-6 plays a central role in the pathogenesis of sepsis. Nu-
merous clinical studies have demonstrated consistently in-
creased IL-6 values in both adult and pediatric septic popu-
lations. Serum levels above 1000 pg/mL have been shown 
to predict sepsis-related death in adult patients (3).
Tsokos et al (34) investigated IL-6 levels in the postmortem 
serum of a series of sepsis and control cases, comparing 
antemortem and postmortem levels. They observed high 
(>1.000 pg/mL) values in most individuals included in the 
sepsis group as well as a notable increase in IL-6 concentra-
tion in postmortem serum compared with IL-6 levels in an-
temortem samples. According to the authors, this increase 
correlated well with the interval after death and suggest-
ed molecule release from cells storing IL-6 due to autolysis 
and decompositional changes.
Soluble interleukin-2 reCePtor
Interleukin-2 (IL-2) is secreted from activated T cells in sev-
eral immunologic processes and is the major growth factor 
for T-lymphocytes. IL-2 acts by binding with a membrane 
IL-2 receptor (IL-2R, CD25), which is widely expressed by 
many leukocytes that include activated B cells, monocytes, 
eosinophil granulocytes, and natural killer cells. Early in the 
activation process, T cells express IL-2R, which consists of 
three subunits (α, β, γ) encoded by different genes. The 
combination of IL-2Rβ and γ can bind IL-2. However, the 
expression of all three subunits is required for the high af-
finity state. In situations where a high expression of mem-
brane IL-2R occurs, the subunit α (IL-2Rα, sIL-2R or sCD25) 
is shed from the cell surface by proteolytic cleavage and 
released into the circulation. sIL-2R release was found to be 
proportional to its membrane bound-expression, and its 
determination was therefore proposed as a useful, indirect 
marker of T- cell activation in several immunologic situa-
tions including various chronic autoimmune diseases, neo-
plastic disorders, acute graft-vs-host disease, chronic liver 
diseases, and sepsis (45-48).
Reichelt et al (49) investigated sIL-2R in the postmortem 
serum of a series of sepsis and control cases, comparing 
antemortem and postmortem levels. They observed in-
creased (>1.000 U/mL) levels in all individuals included 
in the sepsis group and values below the reference limit 
in most control cases. Antemortem levels were generally 
higher than postmortem concentrations. Moreover, using 
linear regression analysis, sIL-2R levels calculated for the 
time of death correlated well with the levels measured in 
antemortem samples.
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liPoPolySACChAride binding Protein
Innate immunity is the first line of defense against mi-
crobial infections. Host organism responses are activated 
when microbial components are recognized by a variety 
of pathogen sensors, stimulating the host defense effector 
system by rapidly triggering proinflammatory processes. 
Among microbial components, lipopolysaccharide (LPS), 
lipo-oligosaccharides (LOS), and their bioactive portion, 
lipodisaccharide lipid A are commonly defined as endo-
toxins. These are potent immune response stimulants and 
even small differences in LPS structure can have a great 
influence on host immune responses. The induction of in-
flammatory responses by endotoxins is achieved by the 
coordinated, sequential action of four principal endotoxin-
binding proteins: LBP (LPS-binding protein), CD14, toll-like 
receptor 4 (TLR4), and MD-2 (myeloid differentiation pro-
tein), herein further discussed (50).
LBP was first described in 1990. It is a 58-kDa glycoprotein 
mainly synthesized in the liver, which is released into circu-
lation as a type I acute-phase reactant. Reference plasma 
level ranges from 5 to 15 µg/mL. LBP levels peak shortly 
after bacteremia or endotoxemia, and remain increased for 
up to 72 hours later (8,51).
LBP interacts with endotoxin-rich bacterial membranes 
and purified endotoxin aggregates, catalyzing endotox-
in monomer extraction and transfer to CD14, which in 
turn transfers endotoxin monomers to MD-2 and to MD-
2–TLR4 complex. The transfer of LPS from CD14 to MD-2, 
coupled with the association of MD-2 to TLR4, is required 
for downstream signaling and initiation of the intracellular 
signal cascade that culminates in transcription factor trans-
location to the nucleus and cytokine biosynthesis. Some 
of these, specifically IL-6, in turn induce the synthesis of 
acute-phase proteins in the liver (50-55).
Forensic use of LBP was investigated by Reichelt et al (49) 
in a series of sepsis-related deaths and control subjects. 
LBP levels were above 10 µg/mL (reference limit in healthy 
subjects) in serum samples obtained prior to death and 
postmortem serum samples obtained during autopsy in 
all septic cases. A notable decrease in LBP levels was ob-
served in the sepsis group, with concentrations still mea-
surable up to 48 hours after death. A less marked decrease 
in LBP levels was also noted in the control cases. Accord-
ing to the authors, the decrease in postmortem serum 
LBP levels correlated well with the interval after death 
in both studied groups and suggested molecule prote-
olysis due to decompositional changes along with irrel-
evant postmortem molecule release from hepatocytes in 
the early postmortem period. The authors concluded that 
increased LBP levels could be considered a reliable diag-
nostic tool for the postmortem diagnosis of sepsis. They 
proposed at least two measurements at different post-
mortem intervals in order to better estimate the most 
probable LBP levels at the time of death by using linear 
regression analysis.
Augsburger et al (56) compared procalcitonin and LBP val-
ues in postmortem serum and pericardial fluid in a series 
of sepsis-related cases and control subjects. They observed 
increased (>10 µg/mL) values in most septic cases and ref-
erence (<10 µg/mL) levels in most control cases, thereby 
confirming a high diagnostic accuracy of LBP in identify-
ing sepsis-related deaths. No associations were found be-
tween postmortem serum and pericardial fluid LBP levels 
in either the septic or control cases.
SCd14-St
CD14, the high-affinity receptor for LPS-LBP complexes, is 
a 55-kDa glycosylphosphatidylinositol-anchored protein 
lacking a cytoplasmic domain. CD14 can only bind LPS in 
the presence of LBP and, although LPS is considered its 
main ligand, CD14 also recognizes other microbial con-
stituents, including the proteoglycans of Gram-positive 
bacteria. CD14 is constitutively expressed in most innate 
immune response cells and exists either in an anchored 
membrane form (mCD14) or in a circulating soluble form 
(sCD14). The latter is a 43-53 kD glycoprotein that derives 
from either protease-mediated membrane CD14 shedding 
or liver synthesis as a type II acute-phase reactant. During 
inflammation, plasma protease activity generates soluble 
CD14 fragments: one of these is a 13-kDa truncated N-
terminal fragment of 64 amino acid residues called sCD14 
subtype (sCD14-ST) or presepsin (50-55,57-63).
By facilitating binding to the CD14 cell membrane mole-
cules, LBP enhances the sensitivity of monocytes and gran-
ulocytes to LPS, whereas the soluble form of CD14 medi-
ates LPS activation of CD14-negative cells (53).
sCD14-ST is normally present in very low concentrations 
in the serum of healthy individuals and has recently been 
suggested as a marker for the diagnosis of sepsis. Indeed, 
preliminary studies have indicated that presepsin values 
significantly differ in healthy individuals, in patients with 
local infection, SIRS, sepsis or severe sepsis (57-63).
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In the forensic setting, increased postmortem serum 
sCD14-ST levels have been found in a series of sepsis-re-
lated deaths using cutoff values ranging from 600 to 1200 
pg/mL. Though postmortem serum sCD14-ST levels, indi-
vidually considered, failed to provide better sensitivity and 
specificity than procalcitonin in detecting sepsis cases, the 
combined determination of procalcitonin and sCD14-ST in 
parallel was proposed as useful in improving the diagnos-
tic performance of each biomarker individually considered 
in situations with elusive, preliminary findings (64).
Soluble triggering reCePtor eXPreSSed on 
Myeloid CellS-1
Triggering receptor expressed on myeloid cells type 1 
(TREM-1) is a recently discovered member of the immu-
noglobulin superfamily engaged as a cell membrane re-
ceptor on the myeloid cell family. TREM-1 expression on 
monocyte and macrophage surfaces was shown to be 
markedly up-regulated in human biological fluids as well 
as tissues infected by gram-positive and gram-negative 
bacteria. The functional significance of TREM-1 was discov-
ered when it was observed that the blockade of TREM-1 
signaling protects mice from the lethal effects of lipopoly-
saccharide-induced septic shock. Moreover, up-regulation 
of cell-surface TREM-1 expression was shown to result in 
marked plasma elevation of the soluble form of the mol-
ecule (sTREM-1) (65-71).
Increased plasma sTREM-1 values, individually consid-
ered or in association with other laboratory parameters, 
have been described in patients with bacterial infections 
and sepsis. Additionally, elevated broncho-alveolar lavage 
fluid sTREM-1 concentrations were found in patients with 
bacterial or fungal pneumonia and increased pleural fluid 
sTREM-1 levels in patients with infectious effusions (72-79). 
However, increased plasma sTREM-1 concentrations were 
also observed in patients with acute pancreatitis and non-
infectious inflammations after traumatic lung contusion or 
pulmonary aspiration syndromes (80-82). In addition, the 
diagnostic and prognostic performances of sTREM-1 in 
sepsis and septic shock was reported to be variable, con-
troversial, and even contradictory according to other clini-
cal studies that reaffirmed the central role of traditional 
laboratory parameters, such as CRP, IL-6, and procalcitonin, 
in distinguishing sepsis from systemic inflammatory re-
sponse syndrome (65).
In the forensic field, sTREM-1 levels were determined 
in postmortem serum, pericardial fluid, and urine 
in septic and control cases. Increased postmortem serum 
sTREM-1 levels (cutoff value 90 pg/mL) were observed in 
sepsis-related deaths, whereas most control cases had 
postmortem serum sTREM-1 levels lower than 90 pg/mL. 
Increased sTREM-1 values were also found in pericardial 
fluid and urine in septic cases. However, postmortem se-
rum sTREM-1 levels did not seem to provide improved 
sensitivity and specificity compared to procalcitonin in de-
tecting sepsis after death, indicating that the simultaneous 
assessment of both biomarkers could eventually help in 
clarifying specific situations characterized by elusive mac-
roscopic, microscopic, and laboratory findings (9).
endoCAn
The vascular endothelium has been demonstrated as play-
ing a critical role in the pathogenesis of sepsis by produc-
ing cytokines and chemotactic factors as well as expressing 
surface adhesion molecules that induce circulating leuko-
cyte migration into tissues. Consequently, there is a strong, 
biological rationale for targeting markers of endothelial ac-
tivation as biomarkers of sepsis (83,84).
In clinical practice, a large number of molecules secreted 
by the endothelial cells have been investigated as poten-
tial biomarkers for the early diagnosis of sepsis. These have 
included regulators of endothelial activation, adhesion 
molecules, as well as mediators of coagulation, permeabil-
ity, and vasomotor tone (84).
Endocan (endothelial cell-specific molecule-1) is a soluble 
50-kDa proteoglycan made up of a mature polypeptide of 
165 amino acids and a single dermatan sulfate chain cova-
lently linked to the serine residue at position 137. The mol-
ecule is naturally expressed by endothelial cells, is highly 
regulated in presence of proinflammatory cytokines and 
proangiogenic molecules and may be considered an accu-
rate marker of endothelial activation. Endocan expression 
was associated with a growing number of pathological 
conditions characterized by neoangiogenesis and vascular 
growth. The molecule was found freely circulating at low 
levels in the serum of healthy subjects and overexpressed 
by several types of human tumors, particularly highly vas-
cularized cancers (85-97).
Additionally, increased endocan levels were described in 
patients with sepsis, severe sepsis, and septic shock com-
pared to healthy individuals, with concentrations related to 
the severity of the disease. Scherpereel et al (83) proposed 
a cutoff value of 1.2 ng/mL, which would provide the best 
109Palmiere and Augsburger: Markers for sepsis diagnosis in the forensic setting
www.cmj.hr
sensitivity (82.50%) and specificity (100%) in identifying 
septic cases vs SIRS cases. Since endothelial injury is pivotal 
in the development of organ failure and shock in sepsis, an 
endothelial marker such as endocan might not only reflect 
the severity of the disease but also represent a promising 
diagnostic and prognostic marker of sepsis (8,84,98).
In the forensic setting, endocan levels have been deter-
mined in postmortem serum in septic and control cases. 
Simultaneous increases in both procalcitonin and endocan 
levels were identified in septic cases only. Endocan concen-
trations were low or undetectable in most control cases, 
irrespective of the postmortem interval, suggesting that 
the molecule is not systematically released into the blood-
stream after death following the onset of decompositional 
changes. Conversely, concentrations over 1.0 ng/mL were 
observed only in control cases characterized by diffuse vas-
cular injuries, presumably indicating endocan leakage in the 
bloodstream due to direct endothelial cell damage (99).
neoPterin
Neopterin (D-erytro-1’,2’,3’-trihydroxypropylpterin), a bio-
chemical product of the guanosine triphosphate pathway, 
was first isolated from human urine in 1965. The discovery 
of neopterin as a marker of T-cell activation dates back to 
the 1980s. The molecule is produced primarily in mono-
cyte/macrophage and related cells when stimulated by 
interferon-γ released from activated T cells. Other cell types 
do not produce measurable amounts of neopterin follow-
ing various stimuli. Therefore, the production of the mole-
cule appears to be closely associated with cellular immune 
system activation. The biological function of neopterin is 
not completely clear. However, it has been demonstrated 
that neopterin has relations with nitric oxide synthesis and 
reactive oxygen metabolites. Based on this, it has been 
postulated that the molecule may be toxic for microorgan-
isms and be part of the proinflammatory and cytocidal ar-
mature of activated human macrophages. The upper limit 
of the reference range is approximately 10 nmol/L ( = 2.5 
ng/mL) (8,100-104).
High neopterin concentrations in serum and urine were 
shown to be a reliable indicator of the severity of viral 
(HIV), bacterial, protozoic, parasitic, or fungi-induced infec-
tions. Correlations between neopterin levels and disease 
states were also found for autoimmune disorders (rheu-
matoid arthritis, systemic lupus erythematosus, Crohn’s 
disease, and autoimmune thyroid diseases). Serum levels 
of neopterin were shown to be elevated in subjects with 
coronary and peripheral artery disease, with concentra-
tions potentially predicting adverse cardiovascular events 
and heart failure development in patients with coronary 
artery disease, acute coronary syndromes, or severe pe-
ripheral artery disease. In various types of malignant dis-
eases, increased neopterin concentrations were indicated 
as predictive in tumor progression, metastasis develop-
ment and mortality. Although not produced by tumor 
cells themselves, increased neopterin concentrations 
most likely reflect the host-defense reaction elicited by 
the aggressiveness of the tumor. Furthermore, the moni-
toring of neopterin concentrations would also allow early 
detection of immunological and infectious complications 
in allograft recipients following kidney, heart, liver, lung, 
pancreas, and bone marrow transplants. Since elevated 
levels are found in infectious and non-infectious inflam-
mations, the specificity of neopterin as a clinical marker of 
bacterial sepsis is, however, limited (101-104).
Forensic use of neopterin was investigated by Ishikawa et al 
(36) and Ambach et al (105,106). Postmortem serum neop-
terin levels over 500 nmol/L were observed in bacterial and 
viral infection-related cases as well as in delayed deaths due 
to trauma, thus confirming systemic inflammatory response 
syndromes and monocyte/macrophage activation.
ConCluSionS
Many advances have been made in the identification of 
novel biomarkers for sepsis diagnosis. However, substantial 
discoveries are yet to be made in this field, both in clinical 
and forensic casework. Although more than 178 biomark-
ers have been identified, it remains controversial which of 
these is the most reliable for the diagnosis of sepsis. None 
of the currently available markers can be used to undoubt-
edly determine whether or not a patient is infected. Simi-
larly, in the forensic field, none of the currently available 
biomarkers can be used to establish a definite diagnosis of 
sepsis-related death. These limits notwithstanding, at pres-
ent procalcitonin represents the most reliable parameter 
for the postmortem diagnosis of sepsis.
Due to the complexity of the sepsis response, several 
authors have postulated that a combination of biomark-
ers, rather than a single laboratory parameter, might be 
more effective in order to obtain early and reliable di-
agnosis of sepsis in living patients. In our opinion, this 
same consideration should be applied to the post-
mortem field, where the diagnosis of sepsis is even 
more challenging.
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We consider that it is not advisable to reach the diagnosis 
of sepsis-related death based on laboratory investigations 
only, especially when biochemical analyses are limited to 
a single parameter. Conversely, in our view, postmortem 
bacteriology and postmortem biochemistry must always 
be part of the diagnostic work-up and results must always 
be interpreted in context, with information from circum-
stantial data and medical records (when available), autop-
sy, histology, and, when feasible, neuropathology and im-
munohistochemistry (1-3,8,107,108).
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